Trials / Completed
CompletedNCT01284322
Fresolimumab In Systemic Sclerosis
OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Boston University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fresolimumab | intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-06-01
- Completion
- 2014-03-01
- First posted
- 2011-01-27
- Last updated
- 2014-07-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01284322. Inclusion in this directory is not an endorsement.